Money

Found 79,792 articles

• Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

  5/22/2023

  Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced a $50.7 million Series D financing.

• Adamis Pharmaceuticals Announces Reverse Stock Split - May 19, 2023

  5/19/2023

  Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.

• Cytek Biosciences Announces $50 Million Stock Repurchase Program

  5/19/2023

  Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law.

• Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 19, 2023

  5/19/2023

  Tempest Therapeutics, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,600 shares of its common stock with an exercise price equal to the closing price of Tempest’s common stock on May 15, 2023, the grant date of the award.

• High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

  5/19/2023

  Regeneron Pharmaceuticals, Inc. and Society for Science announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair, the world's largest global pre-college science and engineering competition, for a project that explored planets that orbit very close around their suns.

• Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 19, 2023

  5/19/2023

  Helius Medical Technologies, Inc. announced that, effective May 18, 2023, its independent directors approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.

• Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) - May 19, 2023

  5/19/2023

  Jaguar Health, Inc. announced that the Company's New Employee Inducement Award Plan, which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company's common stock, par value $0.0001 per share.

• Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

  5/19/2023

  Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.

• Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - May 19, 2023

  5/19/2023

  Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

• Daxor Corporation Announces Proposed Underwritten Public Offering - May 19, 2023

  5/19/2023

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announces that it has commenced an underwritten public offering of shares of its common stock.

• American Aires Inc. Announces Filing of Q1/2023 Financial Statements and MD and A

  5/19/2023

  American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) ("Aires" or the "Company"), a leader in scientifically-proven EMF modulation technology, is pleased to announce the filing of its unaudited Financial Statements and the MD&A for the first quarter of 2023, covering the period January 1 to March 31, 2023

• Telo Genomics Announces Private Placement of Units

  5/19/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the "Offering").

• Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  5/18/2023

  Motus GI Holdings, Inc. announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 4,142,012 shares of its common stock and warrants to purchase up to an aggregate of 4,142,012 shares of common stock, at a purchase price of $0.845 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules.

• Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

  5/18/2023

  Myeloid Therapeutics, Inc. announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures.

• InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 18, 2023

  5/18/2023

  InspireMD, Inc. announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD’s common stock.

• SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor as Non-Opioid Therapeutic for Pain

  5/18/2023

  SiteOne Therapeutics, Inc. today announced that it has received a grant (UG3DA058552) for up to $15 million from the National Institute on Drug Abuse (NIDA) for the development of STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.

• OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

  5/18/2023

  OncoResponse today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

• Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

  5/18/2023

  Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.

• Monogram Orthopaedics Shares Begin Trading Publicly on NASDAQ

  5/18/2023

  Monogram Orthopedics announced it raised $17,216,147 is pleased to announce that its common stock will begin trading on the NASDAQ, May 18, 2023, at approximately 11:00 am EST under the ticker symbol "MGRM."

• Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow

  5/18/2023

  Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2023 financial results after market close on Thursday, May 25, 2023.